Considerations for Innovator Drug Companies Regarding China’s Drug Patent Linkage System - 中国将施行药品专利链接制度——创新药企应如何应变

This article originally appeared in IP Economy magazine.

On June 1, 2021, China will implement a drug patent linkage system that will allow drug companies to resolve patent infringement disputes before the marketing approval of competitor drugs in China.  Paul Hastings’ Global IP Co-Chair Bruce Wexler, Partner Melanie Rupert, and IP associates Mi Zhou, Mark Russell Sperling, and Jake Silvers, offer considerations for innovator drug companies in this rapidly developing area.  A reprint is available at the link below.

Click here for a PDF of the full text